76P Fixed 2-year vs. continuous duration immune checkpoint inhibitors in patients diagnosed with advanced cancer: To continue or not to continue?
The optimal duration of immune checkpoint inhibitors (ICIs) in advanced solid malignancies is unknown. Subsets of patients who experience immune related adverse events (irAEs) maintain durable responses despite limited ICI exposure. When ICI discontinuation isn’t prompted by progressive disease (PD) or irAEs it could potentially be given indefinitely. In numerous sponsor-initiated trials the duration of ICI was fixed at 2-years. In a tertiary cancer centre, we report the real-world practices surrounding stopping or continuing ICIs beyond 2 years in patients diagnosed with advanced cancer.
Authors
- Nicola Cook (ORCID: https://orcid.org/0000-0002-2738-7976)
- M. Robinson (ORCID: https://orcid.org/0000-0002-6303-7121)
- Michael J. Smith (ORCID: https://orcid.org/0000-0002-0786-2733)
- Amanda O’Reilly
Institutions
- University of Manchester (GB)
- The Christie NHS Foundation Trust (GB)
Publication Details
- Journal
- Immuno-Oncology Technology
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1016/j.iotech.2024.100819
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00